Surmodics, Inc. (SRDX)
NASDAQ: SRDX · Real-Time Price · USD
30.75
+0.14 (0.46%)
Mar 28, 2025, 4:00 PM EDT - Market closed
Surmodics Revenue
Surmodics had revenue of $29.92M in the quarter ending December 31, 2024, a decrease of -2.06%. This brings the company's revenue in the last twelve months to $125.45M, down -9.23% year-over-year. In the fiscal year ending September 30, 2024, Surmodics had annual revenue of $126.08M, down -4.91%.
Revenue (ttm)
$125.45M
Revenue Growth
-9.23%
P/S Ratio
3.46
Revenue / Employee
$322,488
Employees
389
Market Cap
439.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2024 | 126.08M | -6.51M | -4.91% |
| Sep 30, 2023 | 132.58M | 32.63M | 32.65% |
| Sep 30, 2022 | 99.95M | -5.19M | -4.93% |
| Sep 30, 2021 | 105.14M | 10.27M | 10.83% |
| Sep 30, 2020 | 94.86M | -5.21M | -5.21% |
| Sep 30, 2019 | Pro | Pro | Pro |
| Sep 30, 2018 | Pro | Pro | Pro |
| Sep 30, 2017 | Pro | Pro | Pro |
| Sep 30, 2016 | Pro | Pro | Pro |
| Sep 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
SRDX News
- 21 days ago - Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
- 21 days ago - FTC sues to block private equity firm's deal to buy medical device coatings maker Surmodics - Reuters
- 7 weeks ago - Top 3 Health Care Stocks You'll Regret Missing This Month - Benzinga
- 7 weeks ago - Surmodics Announces Successful Early Clinical Use of Pounce™ XL Thrombectomy System, Suitable for Non-Surgical Removal of Thrombi and Emboli from Iliac and Femoral Arteries - Business Wire
- 2 months ago - Surmodics Reports First Quarter of Fiscal Year 2025 Financial Results - Business Wire
- 5 months ago - Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Business Wire
- 5 months ago - Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System - Business Wire
- 6 months ago - Surmodics Receives FDA 510(k) Clearance for Pounce™ XL Thrombectomy System, Expanding the Pounce Thrombectomy Platform to Larger Peripheral Arteries up to 10 mm in Diameter - Business Wire